Kinetics of MDSC in Patients Treated Steroids-Ruxolitinib as the First Line Therapy for aGVHD.
10.19746/j.cnki.issn.1009-2137.2022.01.046
- Author:
Jing-Jing YANG
1
;
Bo PENG
2
;
Shu FANG
3
;
Yan WEI
1
;
Hao WANG
1
;
Ying-Xin ZHAO
1
;
Kun QIAN
3
;
Ya-Nan WEN
1
;
Dai-Hong LIU
2
;
Li-Ping DOU
4
Author Information
1. Medical School of Chinese PLA, Beijing 100853, China,Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
3. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China,Nankai University, Tianjin 300071, China.
4. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China,E-mail: lipingruirui@163.com.
- Publication Type:Journal Article
- Keywords:
acute graft versus host disease;
first line therapy;
lymphocyte subsets;
myeloid-derived suppressor cell;
ruxolitinib
- MeSH:
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Kinetics;
Myeloid-Derived Suppressor Cells;
Nitriles;
Pyrazoles;
Pyrimidines;
Retrospective Studies;
Steroids
- From:
Journal of Experimental Hematology
2022;30(1):276-285
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the kinetic characteristics of lymphocyte subsets and myeloid-derived suppressor cell (MDSC) in patients who newly diagnosed intermediate- to high-risk aGVHD and treated with steroids-ruxolitinib as the first line therapy from a single-arm, open clinical trial (NCT04061876).
METHODS:We prospectively observed the efficacy of 23 patients having intermediate- to high-risk aGVHD and treated with steroids-ruxolitinib as the first line therapy. The kinetic characteristics of lymphocyte subsets and MDSC were monitored, and then we compared them in steroids-ruxolitinib group (n=23), free-aGVHD group (n=20) and steroids group (n=23).
RESULTS:Of the 23 patients, the CR rate was 78.26% (18/23) on day 28 after first-line treatment with steroids-ruxolitinib. On day 28 after treatment, patients had lower level of CD4+CD29+ T cells (P=0.08) than that of pre-treatment, whereas levels of other lymphocyte subsets in this study were higher than that of pre-treatment; CD4+CD29+ T cells in CR patients decreased, compared with refractory aGVHD patients. On day 28 of treatment, CD8+CD28- T cells (P=0.03) significantly increased in patients with aGVHD than that in patients without aGVHD, so did CD8+CD28- T / CD8+CD28+ T cell ratio (P=0.03). Compared with patients without aGVHD, patients with aGVHD had lower level of G-MDSC, especially on day 14 after allo-HSCT (P=0.04). Compared with pre-treatment, M-MDSC was higher in CR patients on day 3 and 7 post-treatment (P3=0.01, P7=0.03), e-MDSC was higher on day 28 post-treatment (P=0.01). Moreover, compared with CR patients, M-MDSC was lower in refractory aGVHD patients on day 3 post-treatment (P=0.01) and e-MDSC was lower on day 28 post-treatment (P=0.01). Compared with steroids group, MDSC in steroids-ruxolitinib group was higher, with the most significant difference in M-MDSC (P3=0.0351; P7=0.0142; P14=0.0369).
CONCLUSION:We found that patients newly diagnosed intermediate- to high-risk aGVHD receiving first-line therapy with steroids-ruxolitinib achieved high response rate. Moreover, the novel first-line therapy has a small impact on the immune reconstitution of patients after allo-HSCT. Elevated MDSC might predict a better response in aGVHD patients receiving this novel first-line therapy. M-MDSC responded earlier to steroids-ruxolitinib than e-MDSC, G-MDSC.
